| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 794,900 | 687,500 | 572,600 | 622,100 |
| Cost of revenues | 14,000 | 11,300 | 9,200 | 8,000 |
| Research and development | 250,000 | 244,300 | 263,200 | 195,000 |
| Acquired in-process research and development | 300 | 0 | 100 | 1,000 |
| Selling, general, and administrative | 291,600 | 286,300 | 276,500 | 234,300 |
| Total operating expenses | 555,900 | 541,900 | 549,000 | 438,300 |
| Operating income | 239,000 | 145,600 | 23,600 | 183,800 |
| Unrealized gain (loss) on equity investments | 30,600 | -6,700 | -30,600 | -16,900 |
| Charges associated with convertible senior notes | 0 | 0 | - | - |
| Investment income and other, net | 22,200 | 20,600 | 21,700 | 23,400 |
| Total other income (expense), net | 52,800 | 13,900 | -8,900 | 6,500 |
| Income before provision for income taxes | 291,800 | 159,500 | 14,700 | 190,300 |
| Provision for income taxes | 82,300 | 52,000 | 6,800 | 60,500 |
| Net income | 209,500 | 107,500 | 7,900 | 129,800 |
| Foreign currency translation adjustments, net of tax | -1,600 | -800 | -1,500 | -2,900 |
| Unrealized (loss) gain on available-for-sale debt securities, net of tax | -900 | 2,700 | 1,700 | 9,100 |
| Comprehensive income | 210,200 | 111,000 | 11,100 | 141,800 |
| Basic (in shares) | 99,400,000 | 99,000,000 | 99,700,000 | 101,100,000 |
| Basic (in usd per share) | 2.11 | 1.09 | 0.08 | 1.28 |
| Diluted (in shares) | 102,500,000 | 101,000,000 | 102,500,000 | 104,300,000 |
| Diluted (in usd per share) | 2.04 | 1.06 | 0.08 | 1.24 |
NEUROCRINE BIOSCIENCES INC (NBIX)
NEUROCRINE BIOSCIENCES INC (NBIX)